MAPT and Cognitive impairment: Amyloid or tau PET should not be used as a substitute for a comprehensive clinical examination, which should include a detailed medical and neurobehavioral history, physical examination, mental status testing, blood tests to rule out potentially reversible causes of cognitive impairment, and structural brain imaging.